PU-WS13 is a potent, Grp94-specific Hsp90 inhibitor of the purine scaffold class. PU-WS13 has been shown to reduce the viability of breast cancer cells that express high levels of cell surface HER2 and the viability of human multiple myeloma cells in vitro.
Related Prodcuts:
GW9662; TAS-103; TAS-103 dihydrochloride; BRD73954; L189; SCR7; Ispinesib; Dasabuvir; Ellipticine; Rucaparib; Rucaparib phosphate; Rucaparib camsylate; CB-5083; Maytansinoid DM 1; Mirin; Dasabuvir sodium; Dexrazoxane Hydrochloride; Nedaplatin; CAY10572